Biotechnology Analyst Minter, along with Dr. Kausik “Kosh” Ray, discuss the upcoming readout of Verve’s Phase I heart-1 Study of VERVE-101 in heterozygous familial hypercholesterolemia (HeFH) on an Analyst/Industry conference call to be held on October 25 at 1:30 pm. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VERV:
- William Blair biotech analyst to hold an analyst/industry conference call
- Cathie Wood’s ARK Investment bought 277.8K shares of Verve Therapeutics today
- Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
- Verve Therapeutics: FDA clears IND application for VERVE-101
- Verve Therapeutics to present Phase 1b data on HeFH candidate